期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

二肽基肽酶4抑制剂/二甲双胍固定剂量复方制剂的临床应用专家建议

Experts recommendation for dipeptidyl peptidaseⅣinhibitors/metformin fixed-dose combination therapies in patients with type 2 diabetes mellitus
原文传递
导出
摘要 二肽基肽酶4(DPP-4)抑制剂和二甲双胍联合应用,针对2型糖尿病不同的病理生理缺陷发挥机制互补、协同增效的降糖作用。DPP-4抑制剂/二甲双胍固定剂量复方制剂(FDC)和等剂量DPP-4抑制剂、二甲双胍自由联合相比,具有良好的生物等效性。与两种药物自由联合相比,FDC可简化治疗方案,提高患者治疗依从性。笔者重点围绕DPP-4抑制剂/二甲双胍FDC的有效性和安全性、优势和局限性、适用人群以及使用注意事项等提出建议。
作者 中华医学会内分泌学分会神经与内分泌学组 母义明 朱大龙 赵家军 余学锋 谷伟军 Neuroendocrine Expert Panel,Chinese Society of Endocrinology;Mu Yiming;Zhu Dalong;Zhao Jiajun(不详;Department of Endocrinlolgy,the First Medical Center of PLA General Hospital,Beijing 100853,China;Department of Endocrinology,Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University,Nanjing 210008,China;Department of Endocrinology,Shandong Provincial Hospital,Jinan 250021,China)
机构地区 不详 解放军总医院第一医学中心内分泌科 南京大学医学院附属鼓楼医院内分泌科 山东省立医院内分泌科 华中科技大学同济医学院附属同济医院内分泌科
出处 《中华糖尿病杂志》 CAS CSCD 北大核心 2020年第12期949-953,共5页 CHINESE JOURNAL OF DIABETES MELLITUS
关键词 糖尿病 2型 二肽基肽酶4抑制剂 二甲双胍 固定剂量复方制剂
分类号 R977.15 [医药卫生—药品]
  • 相关文献

参考文献7

二级参考文献99

  • 1Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metfonnin. Diabetes Care, 2007,30 ;890- 895.
  • 2Defronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metfonnin alone. Diabetes Care, 2009,32;1649-1655.
  • 3Gallwitz B, RosenstockJ, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin , a randomised, double-blind, non-inferiority trial. Lancet, 2012,380 ;475483.
  • 4Haak T, Meinicke T,Jones R, et al. Initial combination of linagliptin and metfonnin improves glycaemic control in type 2 diabetes; a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab,2012,14;565-574.
  • 5Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metfonnin compared with metfonnin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab, 2011,13 ;644-652.
  • 6Seck T, Engel S, Golm G, et al. Initial Therapy with the Fixed-Dose Combination ( FDC) of Sitagliptin and Metfonnin (JANUMET?) in Patients with Type 2 Diabetes Mellitus ( T2DM) Provided Superior Glycemic Control vs. Metfonnin Alone, Based on the AACEI ACE Diabetes Algorithm. 2011. Diabetes, 2011 ,60 ( Suppl 1 ) ; A290.
  • 7Charles MA, Eschwege E. Prevention of type 2 diabetes; role of metfonnin. Drugs, 1999,58(Suppll) ;71-73,75-82.
  • 8Asmar M, HolstJ1. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide; new advances. CUIT Opin Endocrinol Diabetes Obes , 2010, 17 ; 57 -62.
  • 9Thondam SK, Cross A, Cuthbertson DJ, et al. Effects of chronic treatment with metfonnin on dipeptidyl peptidase4 activity, glucagon?like peptide I and ghrelin in obese patients with Type 2 diabetes mellitus. Diabet Med, 2012,29; e205-e21O.
  • 10Mannucci E, Tesi F, Bardini G, et al. Effects of metfonnin on glucagon-like peptide-I levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab, 2004,17 ;336-342.

共引文献220

中华糖尿病杂志
2020年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部